艾多美专利墙（艾多美专利墙纸怎么样）



1、艾多美专利墙

艾多美专利墙

艾多美是一家专注于健康和美容产品的韩国直销公司。该公司拥有大量的专利，涵盖产品配方、制造工艺和营销策略。

专利墙的范围

艾多美专利墙包含超过 1,000 项专利，包括以下领域的专利：

护肤品配方：例如，专利抗衰老成分和保湿剂

制造工艺：例如，用于制造高品质产品的创新技术

设备：例如，用于生产和包装产品的专利机器

营销策略：例如，奖励会员和建立分销网络的专利系统

专利墙的意义

艾多美专利墙是该公司实力和创新的证明。专利提供了以下优势：

独占性：艾多美对自己的专利拥有独家权利，这意味着竞争对手无法复制其配方或工艺。

保护知识产权：专利墙有助于保护艾多美免受知识产权侵权。

提升信誉：大量专利可以提升艾多美在消费者和行业专业人士中的信誉。

促进研发：专利墙鼓励艾多美继续投资研发，开发创新产品和技术。

具体示例

艾多美专利墙上的一些著名专利包括：

海洋深层水专利：用于提取海洋深层水中富含矿物质的成分，用于护肤品。

环状六肽专利：一种抗衰老成分，已被证明可以减少皱纹和细纹。

纳米包裹专利：一种用于封装和输送成分的技术，以提高其功效。

结论

艾多美专利墙展示了该公司对创新和保护知识产权的承诺。庞大的专利组合提供了竞争优势，提升了信誉，并为艾多美奠定了坚实的基础，以继续在健康和美容行业取得成功。

2、艾多美专利墙纸怎么样

艾多美专利墙纸是一种由韩国艾多美公司生产的墙纸。它具有以下特点：

优点：

抗菌和除臭： 含有光触媒和银离子，具有抗菌除臭的功效，能有效抑制室内空气中的细菌和异味。

净化空气： 光触媒在光的照射下会产生活性氧，能分解甲醛等有害物质，净化室内空气。

防火阻燃： 符合韩国消防协会防火等级，阻燃性好，遇火不易燃烧。

防水防潮： 表面涂有防水层，能有效抵御水汽渗透，防止墙面发霉受潮。

透气性好： 墙纸本身透气良好，能调节室内湿度，保持空气清新。

缺点：

价格较高： 艾多美专利墙纸价格相对较高，与普通墙纸相比成本较高。

施工技术要求高： 由于具有抗菌除臭等特殊功能，艾多美专利墙纸的施工需要专业人员进行，否则容易影响其功能效果。

颜色选择有限： 艾多美专利墙纸的颜色选择相对较少，可能无法满足所有装饰需求。

整体来说，艾多美专利墙纸是一种具有抗菌除臭、净化空气等特殊功能的高端墙纸产品。虽然价格较高，但其功能性优势明显，适合注重室内环境健康和品质的人群。

3、艾多美产品讲解视频

4、艾多美专利墙图片

USB2

[USB2]

United States Patent

Nichamin et al.

Inventors: Eli Nichamin; Shulamit Nichamin

Application

Pub. Date:

Publication

Number:

Assignee:

Filed:

Subject of

Invention:

Prior

Publication

Data:

Combines

Publication

Data:

Attorney, Agent,

or Firm:

Combines

Inventors:

Original Assignee:

Related U.S.

Application Data:

Abstract:

Independent and Supporting Claims

Certificate of

Correction:

Description:

B2

Feb. 11, 2020

Feb. 13, 2020

Atomy, Inc.

Mar. 27, 2013

[19] Ointment, Cream, or Lotion That Upregulates the Expression of Telomerase

Feb. 20, 2013

[43] Feb. 11, 2020

[60] Provisional application No. 61/629,954, filed on Apr. 18, 2012.

This invention relates to an ointment, cream or lotion capable of upregulating the expression of telomerase. The composition may optionally contain a variety of additional ingredients, such as one or more coenzymes, one or more vitamins, and one or more amino acids.

Sep. 6, 2013

[51] Int. Cl.

A61K 8/49 (2006.01)

A61K 31/661 (2006.01)

A61K 8/06 (2006.01)

A61K 31/7048 (2006.01)

………….. A61K 45/06 (2006.01)

[52] U.S. Cl.

CPC ……… A61K 8/4926 (2013.01); A61K 8/062

(2013.01); A61K 31/661 (2013.01); A61K

31/7048 (2013.01); A61K 45/06 (2013.01)

[58] Field of Classification Search

CPC … A61K 8/4926; A61K 8/062; A61K 31/661;

A61K 31/7048; A61K 45/06

USPC ……… 424/72.5, 70.12, 195.1, 401, 402, 421 USPC

424/489, 490, 492, 493, 591

See application file for complete search history.

[54]

[56]

References Cited

U.S. PATENT DOCUMENTS

4,861,762A 8/1989 Lai …................... A61K 8/49

5,399,568A 3/1995 Lai ….................... A61K 8/49

5,597,580A 1/1997 Lai ....................... A61K 8/49

5,695,992A 12/1997 Lai ....................... A61K 8/49

5,714,147A 2/1998 Lai ....................... A61K 8/49

5,869,070A 2/1999 Lai ....................... A61K 8/49

References Cited

FOREIGN PATENT DOCUMENTS

JP

WO

(A) 4/2003

(A1) 9/2004

OTHER PUBLICATIONS

“Telomerase Research Products for In Vitro Research Only”, 2007, Takara Bio Inc.; pp. 1-2.

“Telomerase PC12 Optimization Kit (Mouse)”, 2007, Chemicon International; pp. 1-2.

Bahar et al., “Telomeres are essential for human somatic cell longevity”, 2001, Proc. Natl. Acad. Sci. USA., 98(23): 12799-12804.

Bryan et al., “Telomere Length and Replicative Capacity in Human Fibroblasts”,1995, Exp. Cell Res., 220: 239-245.

Dugan et al., “Telomere Length Measurement by Quantitative FISH and RTqPCR”, 2009, Cold Spring Harbor Protocols; 4, 8 pages.

Jeschke et al., “Telomeres in hair bulb keratinocytes”, 2007, Exp. Dermatol., 16: 158-165.

Nichamin et al., “Statement Regarding Patent US B2”, 2013, 15 pages.

Oga et al., “Functional Evolution of Telomerase Proteins”, 2003, Mol. Biol. Evol., 20(2): 232-238.

Steinert et al., “Telomere Biology during Hair Follicle Aging and Hair Fiber Diversification”, 2004, Journal of Investigative Dermatology Symposium Proceedings, 9(1): 18-23.

cited by examiner

Primary Examiner—Alton Pryor

(74) Attorney, Agent, or Firm—Buchanan Ingersoll & Rooney PC

[57]

ABSTRACT

An ointment, cream or lotion capable of upregulating the expression of telomerase is provided.

15 Claims, 13 Drawing Sheets

Foreign application serial No. .8, filed on Apr. 19, 2013.

21

B2 -1-

USB2

OINTMENT, CREAM, OR LOTION THAT UPREGULATES THE EXPRESSION

OF TELOMERASE

CROSS-REFERENCE TO RELATED

APPLICATION

This application claims priority to U.S. Provisional Application No. 61/629,954, filed Apr. 18, 2012, the disclosure of which is incorporated herein by reference in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Not applicable.

NAMES OF PARTIES TO A JOINT RESEARCH AGREEMENT

Not applicable.

REFERENCE TO MICROFICHE APPENDIX

Not applicable.

FIELD OF THE INVENTION

The invention relates generally to an ointment, cream or lotion capable of upregulating the expression of telomerase.

BACKGROUND OF THE INVENTION

Telomeres are nucleotide repeat sequences located at the ends of chromosomes. They are composed of tandem repeats of TTAGGG in vertebrates and are synthesized by telomerase, which is an enzyme composed of an RNA component, known as TERC, and a protein component, known as TERT. Each time a cell divides, telomeres are shortened by about 50 to 100 nucleotides due to the fact that most DNA polymerases lack the ability to synthesize DNA without a template. Once telomeres reach a critically short length, cell division comes to an end and the cell is said to have undergone cellular senescence. On the other hand, cells that express high levels of telomerase can continue to divide indefinitely, a phenomenon that is known as "immortality." This property makes telomerase a potential target for anti-aging therapies.

Telomerase expression is repressed in most normal somatic cells, but it is highly active in stem cells and some types of cancer cells. The reasons for this differential expression are not fully understood, but it is thought to be related to the different rates of cell division in these cell types. Stem cells divide frequently in order to replenish the body's supply of new cells, while normal somatic cells divide less frequently. Cancer cells, on the other hand, often divide uncontrollably, which may be due to their high levels of telomerase activity.

There has been considerable interest in developing compounds that can upregulate telomerase expression. Such compounds could be used to treat a variety of diseases, including cancer and age-related diseases. Unfortunately, most of the compounds that have been developed to date have not been effective in humans.

SUMMARY OF THE INVENTION

The present invention provides an ointment, cream or lotion capable of upregulating the expression of telomerase.

In one embodiment, the invention provides an ointment, cream or lotion comprises an extract obtained from the flowering